What is Unchained Labs?
Unchained Labs, founded in 2014 and based in Pleasanton, California, is dedicated to developing innovative products that significantly advance the work of researchers in biologics and gene therapy. Its flagship product, Optim, is recognized as the world's first and only multiplex protein stability platform designed specifically for biologists. This focus positions Unchained Labs at the forefront of enabling critical discoveries and advancements in complex biological research, addressing key challenges in protein analysis and stability.
How much funding has Unchained Labs raised?
Unchained Labs has raised a total of $285M across 6 funding rounds:
Series A
$25M
Series B
$25M
Series C
$13M
Series D
$17M
Unspecified
$50M
Debt
$155M
Series A (2015): $25M with participation from Novo Ventures, Canaan Partners, and TPG Biotech
Series B (2016): $25M led by Novo Ventures, TPG Biotech, and Canaan Partners
Series C (2017): $13M supported by Canaan Partners, Novo Ventures, and TPG Biotech
Series D (2018): $17M featuring TPG Biotech, Canaan Partners, and Novo Ventures
Unspecified (2019): $50M backed by Silicon Valley Bank
Debt (2021): $155M with participation from Golub Capital and MidCap Financial
Key Investors in Unchained Labs
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health. With offices in the U.S. and Israel and billions of dollars under management, Canaan has funded hundreds of startups and supported dozens of IPOs and acquisitions.
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
TPG Biotech
TPG is widely regarded as a global investment firm that focuses on managing alternative assets and supporting business growth across diverse industries. From a third-party perspective, it is seen as a firm that provides investment management, advisory, and capital solutions to institutions and companies worldwide. It operates across areas such as private equity, credit, real estate, and impact investing, helping organizations expand and improve performance.The company is often described as having a collaborative and innovation-driven approach, combining sector expertise with strategic insight to identify opportunities and build long-term value. It serves a wide range of clients including investors, portfolio companies, and business partners, and is recognized for its diversified investment strategies and global presence.
What's next for Unchained Labs?
With substantial enterprise-level and strategic investment backing, Unchained Labs is poised for accelerated growth and product expansion. The company's consistent fundraising history, including significant debt financing in 2021, suggests a strategic approach to scaling operations, enhancing its product portfolio, and potentially expanding its market reach. Future developments are likely to focus on further solidifying its position in the biologics and gene therapy research tools market, leveraging its unique Optim platform to drive innovation and support scientific breakthroughs.
See full Unchained Labs company page
